News

Oregon Infants Sickened By Lead in Recalled Target Baby Food
MONDAY, July 7, 2025 — Two babies in Oregon got sick with lead poisoning after eating baby food from Target that was ...
US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Publix Food Recall Update as 'Foreign Material' Found in Multiple Products
Publix has had to manage several recalls involving both meat and non-meat products since the start of the year.
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Here’s how to get GLP-1 drugs covered by employer health insurance
Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...
American Kratom Association Applauds FDA Crackdown on Dangerous Chemically Manipulated 7-OH, Pseudoindoxyl and 'M' Products
Synthetic products posing as kratom mislead and endanger consumers; AKA urges FDA to take decisive action against violative ...
US judge says layoffs at Department of Health and Human Services were likely unlawful and must be halted
A federal judge has ruled that recent mass layoffs at the US Department of Health and Human Services were likely unlawful and ...
A Promising New AIDS Drug Highlights The Dangers Of Price Controls
The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...
STAT2h
Inside the staff exodus and tanking morale that threaten Makary’s FDA
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
US FDA approves KalVista Pharma's swelling disorder drug
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat ...